Kazia Therapeutics has appointed Dr. Sudha Rao as Chief Scientific Officer, bringing her expertise in epigenetics and oncology drug development to lead the company's research and development. Dr. Rao is the scientific originator behind key programs like paxalisib, a brain-penetrant PI3K/mTOR inhibitor, and innovative platforms targeting PD-L1 and SETDB1 for cancer treatment. Her leadership is expected to advance Kazia's integrated oncology platform strategy, including precision medicine and AI-driven drug discovery. This move strengthens Kazia's pipeline development and biomarker strategies as it progresses clinical trials in various cancers.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
